

CUMULATIVE INDEX 1992

Volume 18

February	SPONDYLOARTHROPATHIES, pages 1-282
May	ANTINUCLEAR ANTIBODIES, pages 283-505
August	SJÖGREN'S SYNDROME, pages 507-717
November	GENETIC FACTORS, pages 719-947

Note: Page numbers of article and issue titles are in **boldface** type.

- A polypeptide, antibodies to, in SLE, 327-328
- A proteins, antibodies to. See *P proteins*.
- ACAs. See *Centromere, antibodies to*.
- Acetylcysteine drops, in dry eye, 605
- Acne, in SAPHO syndrome. See *SAPHO syndrome*.
- musculoskeletal features of, **215-224**
- case histories of, 220-222
- etiology of, 222-223
- in follicular occlusion triad, 216-217
- laboratory evaluation of, 218-219
- prognosis for, 220
- radiographic features of, 219
- treatment of, 219-220
- Acquired immunodeficiency syndrome. See *Human immunodeficiency virus infection*.
- AIDS. See *Human immunodeficiency virus infection*.
- Alanyl-tRNA synthetase, antibodies to (anti-PL-12), 459
- Alleles, definition of, 763
- Alveolitis, lymphocytic, in Sjögren's syndrome, 620-621
- Alzheimer's disease, vs. Sjögren's syndrome, 646
- Aminoacyl-tRNA synthetases, 455-466
- activity of, 455-456
- antibodies to, clinical picture and, 459-462
- epitopes of, 465-466
- features of, 462-463
- types of, 455-459
- complexes of, 464
- features of, 463-464
- ANAs. See *Antinuclear antibodies*.
- Anetholetrithione, in Sjögren's syndrome, 585
- Angioedema, hereditary, C1-inhibitor deficiency in, 906-907
- Ankylosing spondylitis, aging effects on, 160-161
- bacterial antigen persistence in, 857-858
- bacterial triggers for, 851-854
- clinical spectrum of, 2-3
- development of, from undifferentiated spondyloarthropathy, 196-198
- diagnosis of, vs. undifferentiated spondyloarthropathy, 194-196
- duration of, vs. roentgenographic abnormalities, 155, 158
- enthesopathy in, juvenile, 128-129, 133
- muscle hypertonicity and, 170
- epidemiology of, 1-2, 839-840
- juvenile, 124-125
- undifferentiated spondyloarthropathy and, 189-193
- etiology of, 840-842
- genetic factors in. See *Spondyloarthropathy, genetic factors in*.
- gout and, 169-170
- heterogeneity in, 3
- HLA-B27 in, 1-6, 133-134, 837, 840-842
- juvenile, 133-134
- klebsiella infections and, 107-114
- sex hormones and, 153-161, 166, 168-170
- subtypes of, 842-843
- tumor necrosis factor polymorphism and, 177-180, 183
- in inflammatory bowel disease, 24-25

- Ankylosing spondylitis (*Continued*)
 in non-Caucasian populations, 4-6
 in pregnancy, 161
 juvenile, 123-142, 152
 axial involvement in, 129
 course of, 127
 diagnosis of, 132-136
 enthesopathy in, 128-129, 133
 epidemiology of, 124-125
 extra-articular, 130-132
 HLA-B27 in, 133-134
 onset of, 127
 pathogenesis of, 125-127
 peripheral arthropathy in, 128
 seronegative enthesopathy and arthropathy syndrome, 133
 tenosynovitis in, 128-129
 treatment of, 137
 vs. adult-onset, 136
 vs. juvenile rheumatoid arthritis, 134
 leishmania infections and, 27, 95-104, 105-121
 cross-tolerance hypothesis in, 95-97
 historical background of, 106-107
 HLA-B27 and, 107-114
 immunogenetic considerations in, 107-108
 microbiologic evidence for, 113-114
 modifying factor in, 97-98
 molecular mimicry hypothesis in, 98-100
 serologic evidence for, 115-116
 theoretical models explaining, 109-113
 limited forms of, 155
 muscle involvement in, 167-168, 170
 onset age of, sex hormones and, 158
 population associations in, 837-838
 prevalence of, sex ratios in, 153-155, 158, 160
 reactive arthritis and, 27-28
 sex hormones in, 153-175
 aging and, 160-161
 animal model for, 166-167
 clinical studies on, 155, 158
 disease duration and, 155, 158
 female clinical studies on, 162
 human chorionic gonadotropin, 165-166
 Klinefelter's syndrome and, 166
 male clinical studies on, 162-166
 muscle involvement and, 167-168, 170
 onset age and, 158
 operative mechanisms of, 169-170
 pregnancy and, 161
 prevalence ratios and, 153-155, 158, 160
 sexual maturation and, 160
 treatment of, 29-30
 human chorionic gonadotropin in, 165-166
 juvenile, 137
 sex hormones in, 162-166
 tumor necrosis factor polymorphism and, 177-186
 cytokine production and, 181
 genetic aspects of, 178-181
 restriction fragment length polymorphism analysis in, 180, 183
 Anthralin, in psoriatic arthritis, 251
 Antibiotics, in reactive arthritis, 28-30, 856-857
 Antibodies. See also specific antigen, antibodies to; Immunoglobulin(s).
 to rheumatoid arthritis markers, 745
 Anticardiolipin antibodies, in Sjögren's syndrome, 665-666
 Anti-CD4 immunotherapy, genetic considerations in, 919-920
 Anticentromeric antibodies. See Centromere, antibodies to.
 Anti-EJ antibodies, 459
 Anti-Fer antibodies, in polymyositis, 467-468
 Antifibrillar antibodies, in scleroderma, 493
 Antigen(s). See also specific antigen.
 bacterial. See Bacterial antigens.
 nuclear. See Nuclear autoantigens.
 Antigen-antibody complexes (immune complexes), in lupus glomerulonephritis, 432
 in reactive arthritis, 855-856
 Antihistone antibodies. See Histones, antibodies to.
 Anti-Jo-1 antibodies. See Jo-1 antigens, antibodies to.
 Anti-56 kD antibodies, polymyositis, 470-471
 Anti-KJ antibodies, in polymyositis, 468, 476
 Anti-Ku antibodies. See Ku antigens, antibodies to.
 Anti-L5 and anti-L12 antiribosomal antibodies, 384
 Anti-La antibodies. See SS-B/La antigen, antibodies to.
 Anti-Mas antibodies, in polymyositis, 467-468, 475
 Anti-Mi-2 antibodies, in polymyositis, 475
 Antimyosin antibodies, in polymyositis, 472-473
 Antineutrophil cytoplasmic antibodies, in Sjögren's syndrome, 666
 Antinuclear antibodies. See also specific antibody, e.g., SS-A/Ro antigen, antibodies to; SS-B/La antigen, antibodies to; specific disease.
 anti-DNA, 437-454

- antihistone, 415-436
- anti-La. See *SS-B/La antigen, antibodies to*.
- anti-p70/p80 (Ku antigens). See *Ku antigens, antibodies to*.
- anti-Ro. See *SS-A/Ro antigen, antibodies to*.
- anti-Sm. See *Sm antigens, in SLE, antibodies to*.
- anti-SS-A. See *SS-A/Ro antigen, antibodies to*.
- anti-SS-B. See *SS-B/La antigen, antibodies to*.
- assays for, 295-303. See also *specific technique*.
- antigen sources for, 302-303
- comparisons of, 301-302
- enzyme-linked immunosorbent assay (ELISA), 300-301
- gel diffusion/immunoprecipitation, 295-298
- immunoblot test, 298-299
- immunoprecipitation, 299-300
- indirect immunofluorescence, 295
- in diffuse infiltrative lymphocytosis syndrome, 687
- in Sjögren's syndrome, 522, 540, 551-570
- central nervous system, 650
- to mitotic apparatus, 562-563
- to p80-coilin, 563-565
- to SS-A/Ro antigen. See under *SS-A/Ro antigen*.
- to SS-B/La antigen, 540, 545-547, 559-562
- nuclear autoantigens and, 283-310
- Antinuclear antigens, in scleroderma, 484-492
- Anti-OJ antibodies, in polymyositis, 464
- Anti-P antibodies. See *P proteins, antibodies to*.
- Antiphospholipid antibodies, in SLE, 878
- Anti-PL-7 antibodies, in polymyositis, 473
- Anti-PL-12 antibodies, 466
- Anti-PM-Scl antibodies, in polymyositis, 469-470, 475, 477
- in scleroderma, 493-494
- Antiribosomal antibodies, experimental induction of, 385, 387
- in SLE, 377-390
- animal models of, 384-385
- anti-L5 and anti-L12, 384
- anti-P protein, 377-382
- anti-28S rRNA, 382-383
- anti-subunit protein S10, 384
- Anti-RNA polymerase I antibodies, in scleroderma, 492-493
- Anti-Ro autoantibodies. See *SS-A/Ro antigen, antibodies to*.
- Anti-S10 antibodies, 384
- Anti-28S rRNA antibodies, 382-384
- Anti-Scl-70 antibodies. See *Topoisomerase I, antibodies to*.
- Antisignal recognition particle (SRP) antibodies, in polymyositis, 467, 475, 477
- Antisynthetase syndrome, 459, 461-462
- Antitopoisomerase I antibodies. See *Topoisomerase I, antibodies to*.
- Anti-U snRNP (uridine-rich small nuclear ribonucleoprotein) antibodies. See *U snRNP, antibodies to*.
- ARAs. See *Antiribosomal antibodies*.
- Arthralgia, in HIV infection, 260
- in Sjögren's syndrome, treatment of, 707-708
- Arthritis, anti-Jo-1 antibodies in, 461
- in HIV infection, 262
- in skin disorders, 217-218
- psoriatic. See *Psoriatic arthritis*.
- septic, in HIV infection, 263
- Arthritogenic peptide model, in HLA-B27-associated spondyloarthropathy, 11-21
- exogenous peptide binding in, 17-19
- exogenous-endogenous peptide exchange in, 15-16
- peptide presentation in, 15
- Aspirin, in juvenile ankylosing spondylitis, 137
- Autoantibodies. See also *Antinuclear antibodies*; and under *specific antigen*, e.g., *SS-A/Ro antigen*.
- definition of, 283
- in diffuse infiltrative lymphocytosis syndrome, 687
- in Sjögren's syndrome, 522-523, 525, 539-540
- central nervous system, 650-651, 655, 660, 663-666
- in SLE, 871-882
- nuclear. See *Antinuclear antibodies*.
- Autoantigens. See also *specific antigen*.
- cloning of, 288-290
- definition of, 283
- nuclear. See *Nuclear autoantigens*.
- recombinant, authentication of, 290-291
- tolerance to, in immunotherapy, 923-924
- Autoepitopes, of nuclear autoantigens, 294-295
- Autoimmune disease, antinuclear antibodies in. See *Antinuclear antibodies*.
- positive selection in, rheumatoid arthritis and, 737, 799-800
- Azathioprine, in psoriatic arthritis, 252
- in Sjögren's syndrome, 666, 708

- B lymphocytes, in DNA response, 444-445
 in histone response, 428-430
 in ribonucleoprotein response, 328-329
 in SLE, 345
- Bacterial antigens. *See also Arthritogenic peptide model; Chlamydial infections; Klebsiella infections.*
 in campylobacter infections, 37, 43
 in juvenile ankylosing spondylitis, 126
 in reactive arthritis, 37-48, 49-66
 antigen presenting cell in, 57
 HLA-B27 and, 59-60
 identification in joint, 50-51
 immune response in, 51-59
 immune system in, 39-40
 lipopolysaccharide role in, 37-38, 43-44
 microbe-host interaction in, 38
 microorganism types, 37-38, 40-43
 superantigens, 58
 T cell role in, 55-57
 transportation to joints, 43
 in salmonella infections, 23-24, 37-39, 41-44
 in shigella infections, 23, 37-39, 43
 in spondyloarthropathies, 851-858
 in yersinia infections, 23-24, 37-44, 51-52
- Biliary cirrhosis, primary, antientromeric antibodies in, 487
 antihistone antibodies in, 424
 tumor necrosis factor polymorphism in, 181-182
 Sjögren's syndrome and, 630
- Biopsy, lacrimal glands, 594
 salivary glands, 582
- Bla idotype, of immunoglobulin M, 815
- Blepharitis, vs. dry eye, 595-596, 701-702
- Blink reflex, in Sjögren's syndrome, 649
- Bone involvement, in SAPHO syndrome. *See SAPHO syndrome.*
- Brain, Sjögren's syndrome of. *See under Central nervous system.*
- Bromhexine, in Sjögren's syndrome, 585
 dry eye, 605
 dry mouth, 703
- Bronchoalveolar lavage, in Sjögren's syndrome, 620
- C protein, antibodies to, in SLE, 328
- CI, inhibitor of, deficiency of, 906-907
- C2, deficiency of, in rheumatic disease, 896-898
 genetics of, 898
- C4, genetics of, 894-898
- Calreticulin, SS-A/Ro antigen and, 340, 556-557
- Campylobacter infections, reactive arthritis in, 37, 43
- Cancer, with scleroderma, antibodies and, 490
- Candidiasis, chronic erythematous, in Sjögren's syndrome, 572, 584-585, 702-703
- Cardiovascular disease, in juvenile ankylosing spondylitis, 132
- Caries, dental, in Sjögren's syndrome, 572-573, 584, 702
- cDNA, cloning of, 288
 recombinant, 284, 286
- Celiac disease, Sjögren's syndrome with, 628
- Cellulitis, of scalp, musculoskeletal features of, 215-224
- Central nervous system, diffuse infiltrative lymphocytosis manifestations in, 686
 Sjögren's syndrome manifestations in, 614, 637-671
 autoantibodies in, 665-666
 clinical features of, 644-645
 diagnosis of, 647-651
 HIV infection with. *See Diffuse infiltrative lymphocytosis syndrome.*
 immunogenetics of, 651
 immunopathogenesis of, 662-664
 nonfocal disease, 645-646
 pathogenesis of, 662-666
 recognition of, 641-642
 spectrum of, 644-645
 treatment of, 666-668
 vascular disease and, 664-665
 vs. multiple sclerosis, 651-656
 vs. systemic lupus erythematosus, 656-661
- Centromere, antibodies to, antitopoisomerase I antibodies and, 491-492
 CENP-A, 484-485
 CENP-B, 485-486
 CENP-C, 485
 clinical significance of, 486-488
 detection of, 486-487
 idiotypes of, 491
 in scleroderma, 491-492
 isotypes of, 487-488
 prognostic significance of, 487
 as antigens, 484-486
- Cerebrospinal fluid analysis, in Sjögren's syndrome, 649, 653-655, 660
- Cheilitis, in Sjögren's syndrome, 572, 703
- Chest wall, SAPHO syndrome effects on, 227, 229-230
- Chlamydial infections, in spondyloarthropathies, 852, 856-857
 reactive arthritis in, 23, 37-38, 43
 genetic factors in, 839-840
 treatment of, 29

- Reiter's syndrome in, 67-79, 85-86
 cellular injury mechanisms, 72-75
 genetic factors in, 839-840
 latent, 73-75
 microorganism presence in synovium, 69-72
 pathogenesis of, 68-69
 treatment of, 75
- Chlorambucil, in diffuse infiltrative lymphocytosis syndrome, 689
 in Sjögren's syndrome, 708
- Chloroquine, in psoriatic arthritis, 252
- Chromatin, histones in, 417
- Chronic obstructive airway disease, in Sjögren's syndrome, 619
- Cirrhosis, Sjögren's syndrome and, biliary, 630
 liver, 630
- Cloning, of autoantigens, 288-290
 authentication of, 290-291
 of DNA, 284, 286
- Cognitive dysfunction, in Sjögren's syndrome, 645-646
- Coiled body, nuclear, in Sjögren's syndrome, 563-565
- Colchicine, in SAPHO syndrome, 240
- Colitis, ulcerative, genetic factors in, 839
- Collagen-induced arthritis disease model, rheumatoid arthritis susceptibility and, 801-802
- Complement receptor 1, genetics of, 899-904
- Complement receptor 2, genetics of, 904-906
- Complement receptor 3, genetics of, 906
- Complement system, deficiencies in, anti-Ro antibodies in, 347
 in SLE, 866-871
 genetics of, 893-914
 C1-inhibitor, 906-907
 C2, 898
 C4, 894-898
 complement receptor 1, 899-904
 complement receptor 2, 904-906
 complement receptor 3, 906
 decay accelerating factor, 907
 Factor B, 898-899
 major histocompatibility complex, 893-898
 membrane attack complex inhibitor, 907
 membrane cofactor protein, 907
- Computed tomography, in Sjögren's syndrome, central nervous system, 648
- Conjunctivitis, arthritic symptoms with. See *Reiter's syndrome*.
- Corticosteroids, in diffuse infiltrative lymphocytosis syndrome, 689
 in juvenile ankylosing spondylitis, 137
 in psoriatic arthritis, 251-252
 in SAPHO syndrome, 240
 in Sjögren's syndrome, 666
 in skin disorders, with musculoskeletal features, 219
 in spondyloarthropathy with uveitis, 148
 in undifferentiated spondyloarthropathy, 198
- Cough, in Sjögren's syndrome, 618-619
- Counterimmunoelectrophoresis, for antinuclear antibody assay, 297-298
- Coxsackie viruses, in myositis-specific antibody production, 475
- Creatinine phosphokinase, in ankylosing spondylitis, 168
- CREST syndrome, anticentromeric antibodies in, 484, 486-487
- Crohn's disease, genetic factors in, 839
 Sjögren's syndrome with, 628
- Cross-tolerance hypothesis, ankylosing spondylitis pathogenesis, 95-97
- Cryoglobulins, in Sjögren's syndrome, 521
- Cutaneous lesions. See *Skin disorders*.
- Cutaneous lupus erythematosus, anti-Ro antibodies in, 347
- Cyclophosphamide, in Sjögren's syndrome, 666-667, 708
- Cyclosporine, in dry eye, 605
 in HIV-related spondyloarthropathy, 264
 in psoriatic arthritis, 251-252
- Cytokines, production of, in tumor necrosis factor polymorphism, 181
- Cytoplasmic antigens, antibodies to. See also *Antiribosomal antibodies*.
 in polymyositis, 466-468
- Decay accelerating factor, in autoimmune disease, 907
- Dementia, in Sjögren's syndrome. See under *Central nervous system*.
- Dental caries, in Sjögren's syndrome, 572-573, 584, 702
- Depression, in Sjögren's syndrome, 707
- Dermatitis, lupus, anti-Ro antibodies in, 347-348
- Determinant-induced unresponsiveness, tolerance to, 923-924
- Determinants, of human leukocyte antigens, 763
- Diabetes mellitus, Factor B deficiency in, 899
 tumor necrosis factor polymorphism in, 181-182
- Diclofenac, in juvenile ankylosing spondylitis, 137

- Dietary modification, in psoriatic arthritis, 251-252
- Diffuse infiltrative lymphocytosis syndrome, 661-662, **683-697**
 antigenically driven mechanisms in, 690-691
 clinical course of, 687-688
 clinical features of, 685-686
 complications of, 687-688
 diagnosis of, 687
 epidemiology of, 684-685
 immunogenetics of, 693-694
 lymphoma in, 688, 690
 ovine visna maedi virus disease and, 694
 T-cell receptor usage in, 691, 693
 treatment of, 688-690
 vs. Sjögren's syndrome, 684
- Dissecting cellulitis, of scalp, musculoskeletal features of, **215-224**
- DNA, antibodies to, **437-454**
 assays for, 438
 binding of, 447
 clinical expression of, 438-440
 cross reactivity with antihistone antibodies, 427
 ds type, 438-439, 441-442
 experimental induction of, 441-442
 idiotypes of, 446, 448-450
 in immunopathology, 440-441
 in normal immunity, 448-450
 in SLE, 880
 molecular analysis of, 445-448
 production of, mechanisms of, 443-445
 ss type, 438-439, 441-442
- as antigen, 438
 bacterial, immunogenicity of, 449-450
 complementary (cDNA), cloning of, 288
 recombinant, 284, 286
 genomic, 284
 Ku antigens interaction with, 401-402
 recombinant, authentication of, 290
 preparation of, 284-286
 structure of, 438
- Double immunodiffusion technique, for antinuclear antibodies, 297-298
 for antiribonucleoprotein antibodies, 320
 for antitopoisomerase I antibodies, 489
 for Ro antigens and antibodies, 338-339
- Dry-induced lupus. See *Lupus, drug-induced*.
- Dry eye, in diffuse infiltrative lymphocytosis syndrome, 685
 in Sjögren's syndrome, **591-608**
 clinical features of, 594-598
 diagnosis of, 598-600, 675-677
 normal tear film and, 591-594
 treatment of, 601-606, 677-679, 700-702
- Dry mouth, differential diagnosis of, 580-581
 in diffuse infiltrative lymphocytosis syndrome, 685
 in Sjögren's syndrome, 572
 pathogenesis of, 519-521
 treatment of, 583-586, 702-703
- Dry nose, in Sjögren's syndrome, 703-704
- Dry skin, in Sjögren's syndrome, 609-610, 704
- Dry trachea, in Sjögren's syndrome, 618-619
- Dysphagia, in Sjögren's syndrome, 625-627
- Edema, pitting, with synovitis, vs. late-onset spondyloarthropathy, 193, 195
- Electroencephalography, in Sjögren's syndrome, 649
- Electrophysiologic studies, in Sjögren's syndrome, central nervous system, 649, 653
- ELISA. See *Enzyme-linked immunosorbent assay*.
- Enthesopathy. See also *Polyenthesitis*.
 in ankylosing spondylitis, muscle hypertonicity and, 170
 in juvenile ankylosing spondylitis, 128-129, 133
 in undifferentiated spondyloarthropathy, 195
- Environmental factors, in rheumatoid arthritis, 731, 795-762
- Enzyme-linked immunosorbent assay, for anticentromeric antibodies, 487
 for antihistone antibodies, 417-418
 for antinuclear antibodies, 300-301
 for antiribonucleoprotein antibodies, 320-321
 for antitopoisomerase I antibodies, 489
- Epidermolysis bullosa acquisita, procollagen antibodies in, 880-881
- Epitopes. See also *specific antigen*.
 shared. See *Shared epitope hypothesis*.
 within autoantigens, 294-295
- Epstein-Barr virus, antigens of, amino acid sequences matching rheumatoid arthritis markers, 733-734
 in Sjögren's syndrome pathogenesis, 531-532, 579-580
- Epstein-Barr virus receptor (CR2), genetics of, 904-906
- Erythema multiforme-like lesions, in Sjögren's syndrome, 611
- Erythema perstans, in Sjögren's syndrome, 611

- Erythromycin, in Reiter's syndrome, 87-88
- Escherichia coli* heat shock protein antigens, amino acid sequences matching rheumatoid arthritis markers, 733-734
- Esophagus, Sjögren's syndrome manifestations in, 625-627
- Estrogens, ankylosing spondylitis manifestations and, 162
- Evoked responses, in Sjögren's syndrome, central nervous system, 649, 653
- Experimental allergic encephalomyelitis, T lymphocyte receptor-based immunotherapy in, 922
- Eye, Sjögren's syndrome manifestations in, 519-521, 591-608
clinical features of, 594-598
diagnosis of, 598-600, 675-677
normal tear film and, 591-594
pathogenesis of, 519-521
treatment of, 601-606, 677-679, 700-702
- Factor B, genetics of, 898-899
- Fatigue, in Sjögren's syndrome, 706-707
- Felty's syndrome, antihistone antibodies in, 423
HLA-DR4 antigen in, 750-751
- Female, ankylosing spondylitis in. See *Ankylosing spondylitis, sex hormones in.*
- Fer antigens, antibodies to, in polymyositis, 467-468
- Ferritin, in Sjögren's syndrome, 706
- Fibrillarin, antibodies to, in scleroderma, 493
- Fibrosis, pulmonary, in Sjögren's syndrome, 621-622
- Fluorescein, in tear flow assessment, 597
- Flurbiprofen, in juvenile ankylosing spondylitis, 137
in Sjögren's syndrome, 708
- Follicular occlusion triad, musculoskeletal features of, 216-217
- Gastritis, atrophic, in Sjögren's syndrome, 627
- Gastrointestinal system, diffuse infiltrative lymphocytosis manifestations in, 686
Sjögren's syndrome manifestations in, 623-635. See also under *Salivary glands.*
esophagus, 625-627
liver, 629-630
pancreas, 629
small intestine, 628
stomach, 627
spondyloarthropathies and, 23-35. See also *Bacterial antigens.*
ileal bypass arthritis, 24
inflammatory bowel disease arthritis, 24
inflammatory lesions, 25
nonsteroidal anti-inflammatory drugs and, 25-26
pathogenesis and, 27-28
reactive arthritis, 23-24
treatment of, 28-30
- Gel diffusion techniques, in antinuclear antibodies assay, 295-298
- Genetic factors, as disease markers, 719-727
clinical correlations with, 721-722
drug development and, 725-726
gene identification in, 722
gene rearrangement and, 722-723
susceptibility gene pathogenesis and, 723-724
in anti-Ro antibody formation, 349
in diffuse infiltrative lymphocytosis syndrome, 693-694
in immunotherapy, 915-925
in myositis-specific antibody production, 475
in rheumatic disease, complement system and. See *Complement system.*
in rheumatoid arthritis, 729-740. See also under *Shared epitope hypothesis.*
environmental factors and, 731, 795
HLA genotyping in, 785-792
immunoglobulin V genes in, 809-836
immunologic factors and, 731-738
limitations of, 729-730
population associations in, 741-759
T-lymphocyte receptor-HLA interaction in, 793-808
- in Sjögren's syndrome, 523-525, 539-550
central nervous system, 651
familial aggregation, 539-540, 548
human leukocyte antigens in, 541-547
markers, 548
T-cell receptor antigens in, 541, 547-548
- in spondyloarthropathy. See under *Spondyloarthropathy.*
- in systemic lupus erythematosus, 865-892
autoantibodies, 871-882
complement gene defects, 866-871
immunoglobulin genes, 882-883
major histocompatibility complex antigens, 871-882
T-cell receptor genes, 882
tumor necrosis factor genes, 883

- Genotyping, of human leukocyte antigens, in rheumatoid arthritis, 785-792
- Glomerulonephritis, in SLE, anti-DNA antibodies in, 440-441
antihistone antibodies in, 432
- Glycyl-tRNA synthetase, antibodies to (anti-EJ antibodies), 459
- Gold, in psoriatic arthritis, 252
- Gout, ankylosing spondylitis and, 169-170
- Greenland, postvenereal Reiter's syndrome in, 81-93
- Growth factors, in tear film, 592
- Guanosine phosphate, antibodies to, in Sjögren's syndrome, 666
- Gut. See *Gastrointestinal system*.
- Heart block, in neonatal lupus syndrome, 347-348, 363-365
- Heat shock proteins, in rheumatoid arthritis, 733-734
in spondyloarthropathy, 178
- Hemorrhage, cerebral, in Sjögren's syndrome, 663
- Hepatitis, in diffuse infiltrative lymphocytosis syndrome, 686
neonatal, anti-Ro antibodies in, 348
Sjögren's syndrome and, 630
- Herbal medicines, in Sjögren's syndrome, 679-682
- Hidradenitis suppurativa, musculoskeletal features of, case histories of, 220-222
etiology of, 222-223
in follicular occlusion triad, 216-217
laboratory evaluation of, 218-219
prognosis for, 220
radiographic features of, 219
treatment of, 219-220
- Histidyl-tRNA synthetase, antibodies to. See *Jo-1 antigens, antibodies to*.
- Histones, 415-436
antibodies to, assays for, 417-419
cross reactivities of, 426-427
in drug-induced lupus, 421-423, 430-431
pathogenesis of, 431
in Felty's syndrome, 423
in juvenile rheumatoid arthritis, 424
in paraneoplastic syndromes, 424
in primary biliary cirrhosis, 424
in rheumatoid arthritis, 423
in SLE, 419-421
animal models of, 424-426
diagnostic value of, 430-431
pathogenesis of, 431-432
production mechanism of, 427-430
pathogenetic effects of, 431-432
in chromatin formation, 417
structure of, 415-417
types of, 415-416
- HIV infection. See *Human immunodeficiency virus infection*.
- HLA. See also *Human leukocyte antigens; Major histocompatibility complex*.
- HLA-B27, gene of, organization of, 843-847
in ankylosing spondylitis, 840-842
juvenile, 133-134
klebsiella infections and, 107-114
sex hormones and, 153-161, 166, 168-170
tumor necrosis factor polymorphism and, 177-180, 183
in psoriatic arthritis, 249
in reactive arthritis, 59-60
in SAPHO syndrome, 238
in spondyloarthropathy, 1-6, 840-842
arthritogenic peptide model and, 11-21
bacterial antigens and, 44, 107-114
bacterial triggers and, 852-855, 857-858
population associations of, 837-838
undifferentiated. See *Spondyloarthropathy, undifferentiated*.
peptide antigens presented by, 848-850
structure of, 798-799, 843-847
subtypes of, 842-843, 845-847
transgenic rat model for, 851
- HLA-DP, in rheumatoid arthritis, 753
- HLA-DQ, in rheumatoid arthritis, 753
- HLA-DQB, negative association with rheumatoid arthritis, 752
- HLA-DR1, in rheumatoid arthritis, 732, 735-737, 795
HLA-DR4 compared with, 771-772
population associations of, 744-748, 750-753
- HLA-DR2, in SLE, 874, 876, 879
negative association with rheumatoid arthritis, 752
- HLA-DR3, in SLE, 874, 880
- HLA-DR4, in rheumatoid arthritis, 732-737, 785-791, 794-795
clinical heterogeneity and, 787-790
determinants of, 763
early-onset, 777
genetic heterogeneity and, 787-790
homozygosity of, 777-778
population associations of, 741-753, 767-769
predictive risk ratios for, 790-791
serologic identification of, 766-767
shared epitopes and, 769-772
specificity of, 763
in SLE, 878-879

- HLA-DR5, negative association with rheumatoid arthritis, 752
- HLA-DR6, in rheumatoid arthritis, 774-775
- HLA-DR7, in SLE, 878
- HLA-DR10, in rheumatoid arthritis, 744-745, 748-751, 775-776
- Human chorionic gonadotropin, in ankylosing spondylitis, 165-166
- Human immunodeficiency virus infection, Reiter's syndrome and, 267-276
- Sjögren's syndrome in, 342. See also *Diffuse infiltrative lymphocytosis syndrome*.
- spondyloarthropathy and, 257-266, 855
- animal models for, 264
- clinical aspects of, 260-263
- epidemiology of, 258-259
- laboratory findings in, 263
- pathogenesis of, 264
- treatment of, 264
- Human leukocyte antigens. See also *Major histocompatibility complex*; specific antigen, e.g., HLA-B27.
- anti-La antibodies and, 361-362
- anti-Ro antibodies and, 343-346
- antitopoisomerase antibodies and, 490
- determinants of, 763
- in psoriatic arthritis, 249, 839
- in rheumatoid arthritis, determinants of, 798-799
- genotyping of, 785-792
- polymorphism of, 798-799
- in Sjögren's syndrome, 526, 541-542
- myositis-specific antibodies and, 475
- specificity of, 763
- terminology of, 763
- Humidification, in dry eye, 602, 702
- Hydralazine-induced lupus, antihistone antibodies in, 422-423, 430-431
- C4 deficiency and, 897
- Hydroxychloroquine, in psoriatic arthritis, 252
- in Sjögren's syndrome, 708
- Hypergammaglobulinemia, Waldenström's, Sjögren's syndrome with, 611
- Hyperostosis, in SAPHO syndrome. See *SAPHO syndrome*.
- Ibuprofen, in juvenile ankylosing spondylitis, 137
- Ileal bypass arthritis, 24
- Immune complexes, in lupus glomerulonephritis, 432
- in reactive arthritis, 855-856
- Immune response, to bacterial antigens, in reactive arthritis, 39-40
- Immunity, anti-DNA antibody expression in, 448-450
- Immunoassays, for nuclear autoantibodies. See *Antinuclear antibodies, assays for*.
- Immunoblot test, for anticentromeric antibodies, 487
- for antihistone antibodies, 417-418
- for antiribonucleoprotein antibodies, 323, 325
- for anti-Ro antibodies, 340
- for antitopoisomerase I antibodies, 489
- for autoantibodies, 298-299
- for Ro antigen, 339
- in ribonucleoprotein complex study, 287
- Immunodeficiency, rheumatoid arthritis severity and, 731
- Sjögren's syndrome symptoms in. See *Diffuse infiltrative lymphocytosis syndrome*.
- Immunodiffusion technique, double. See *Double immunodiffusion technique*.
- Immunofluorescence assay, indirect, for anticentromeric antibodies, 486-487
- for antinuclear antibodies, 296-297
- for antiribonucleoprotein antibodies, 319-320
- Immunogenetics. See also *Genetic factors*.
- of Sjögren's syndrome, 539-550
- Immunoglobulin(s), classes of, in centromere antigen response, 487-488
- in La antigen response, 367-368
- in topoisomerase I response, 490
- genes of, in SLE, 882-883
- rearrangements in, in Sjögren's syndrome, 526-528
- structures of, 810-811
- in tear film, 593
- V genes of, B1a idiotype, 815
- in normal individuals, 818-819
- in rheumatoid arthritis, 809-836
- idiotypes of, 815-818
- polymorphisms of, 826-828
- rheumatoid factor activity and, 812-815
- rheumatoid factor use of, 819, 822-826
- structural considerations in, 810-811
- Po idiotype, 814-815
- Wa idiotype, 812-814
- Immunoglobulin A, in ankylosing spondylitis, 114-116
- Immunoglobulin M, cross reactivity with antihistone antibodies, 427
- idiotypes of, 812-818
- in Sjögren's syndrome, 521-522

Immunoglobulin M (*Continued*)

- V genes of, in rheumatoid arthritis, rheumatoid factor activity and, 812-815
- Immunologic factors, in rheumatoid arthritis, 731-738
- shared epitope hypothesis and, 732-738
- Immunologic mechanisms, in psoriatic arthritis, 249-250
- Immunoprecipitation assay, for antinuclear antibodies, 297-298
- for antiribonucleoprotein antibodies, 321-325
- for anti-Ro antibodies, 340
- for autoantigens, using autoantibodies, 299-300
- for ribonucleoprotein complexes, 287
- for Ro antigen, 339
- Immunosuppressive therapy, in diffuse infiltrative lymphocytosis syndrome, 689
- in Sjögren's syndrome, 666, 668
- Immunotherapy, genetic considerations in, 915-925
- anti-CD4 immunotherapy, 919-920
- determinant-induced unresponsiveness, 923-924
- major histocompatibility complex blockade, 920-921
- T-cell receptor-based, 921-923
- Impression cytology, in dry eye evaluation, 599-600
- Indirect immunofluorescence assay, for anticitromeric antibodies, 486-487
- for antinuclear antibodies, 295
- for antiribonucleoprotein antibodies, 319-320
- Indomethacin, in juvenile ankylosing spondylitis, 137
- Infections, immune system impacts of, rheumatoid arthritis and, 733-734
- in spondyloarthropathy. *See also Arthritogenic peptide model; Bacterial antigens.*
- psoriatic arthritis, 250-251
- reactive arthritis, 23-24
- respiratory, in Sjögren's syndrome, 619
- Infectious mononucleosis, in Sjögren's syndrome pathogenesis, 531-532
- Inflammatory bowel disease, arthritis with, 24-25
- genetic factors in, 839
- juvenile ankylosing spondylitis and, 132
- SAPHO syndrome and, 236-237
- Integrins, in Sjögren's syndrome, 521
- Interferons, in Sjögren's syndrome, 533
- Interleukins, in psoriatic arthritis, 250
- in Sjögren's syndrome, 529-533
- Interstitial lung disease, in antisynthetase syndrome, 461
- Interstitial pneumonitis, in Sjögren's syndrome, 621-622
- Isoleucyl-tRNA synthetase, antibodies to (anti-O), 464
- Isoniazid-induced lupus, C4 deficiency and, 897
- Japan, Sjögren's syndrome treatment in, 673-682
- Jo-1 antigens, antibodies to, 455-457
- diagnostic use of, 473-474
- in arthritis, 461
- in polymyositis, 459, 461-462
- production of, 474
- epitopes of, 465
- HLA associations of, 475
- viral interactions of, 476
- Juvenile ankylosing spondylitis. *See under Ankylosing spondylitis.*
- Juvenile rheumatoid arthritis, antihistone antibodies in, 424
- vs. juvenile ankylosing spondylitis, 134
- Kampo medicines, in Sjögren's syndrome, 680-682
- 56 kD antigens, antibodies to, in polymyositis, 470-471
- Keratitis, filamentary, in Sjögren's syndrome, 520
- Keratoconjunctivitis sicca. *See Dry eye.*
- Kidney, diffuse infiltrative lymphocytosis syndrome in, 686
- dysfunction, in juvenile ankylosing spondylitis, 132
- KJ antigens, antibodies to, in polymyositis, 468, 476
- Klebsiella infections, ankylosing spondylitis and, 27, 95-104, 105-121
- cross-tolerance hypothesis in, 95-97
- historical background of, 106-107
- HLA-B27 and, 107-114
- immunogenetic considerations in, 107-108
- microbiologic evidence for, 113-114
- modifying factor hypothesis in, 97-98
- molecular mimicry hypothesis in, 98-100
- serologic evidence for, 115-116
- theoretical models explaining, 109-113
- spondyloarthropathies and, 852-853
- Klinefelter's syndrome, ankylosing spondylitis and, 166

- Ku antigens, 391-414**
 antibodies to, 403-410
 in autoimmune disease, 408-410
 in mixed connective tissue disease, 404
 in polymyositis, 471-472
 in scleroderma-polymyositis overlap syndrome, 393, 403-404
 incidence of, 403-404
 murine, 406-408
 specificities of, 404, 406-408
 function of, 402-403
 interaction with DNA, 401-402
 structure of, 393-401
 p70, 394-397
 p80, 397
 p70/p80 complex, 398-399
 species variation in, 399-401
 vs. other nuclear factors, 397-398
- Ku-2 factor, structure of, 398**
- L5 and L12 antiribosomal antibodies, 384**
La antigen. See SS-B/La antigen.
Lacrimal glands, biopsy of, 594
 in Sjögren's syndrome, histology of, 525-526
 manifestations in, 519-521
 pathogenesis and, 532-533
 stimulation of, for Schirmer test, 675-677
- Leukotrienes, in psoriatic arthritis, 250**
Lipopolysaccharides, in reactive arthritis, 37-38, 43-44, 857
- Liver, Sjögren's syndrome manifestations in, 629-630**
- Lung(s), diffuse infiltrative lymphocytosis manifestations in, 685**
 interstitial disease, in antisynthetase syndrome, 461
 Sjögren's syndrome manifestations in, 617-623
 chronic obstructive airway disease, 619
 interstitial pneumonitis, 621-622
 lymphocytic alveolitis, 620-621
 lymphoma, 622-623
 pseudolymphoma, 622-623
 recurrent infections, 619
 tracheobronchial desiccation, 618-619
 xerotrachea, 618-619
- Lupus, drug-induced, antihistone antibodies in, 421-423**
 diagnostic value of, 430-431
 hydralazine, 422-423, 430-431
 pathogenesis of, 431
 procainamide, 422, 430-431
 production of, 430
 C4 deficiency and, 897
- neonatal. *See Neonatal lupus syndrome.*
 with complement deficiencies, anti-Ro antibodies in, 347
- Lupus erythematosus, cutaneous, anti-Ro antibodies in, 347**
 neonatal, autoantigens in, 552, 558-559
 subacute cutaneous, autoantigens in, 552, 558-559
 systemic. *See Systemic lupus erythematosus.*
- Lupus precipitin. See Sm antigens, in SLE, antibodies to.**
- Lupus psychosis, anti-P antibodies in, 379-381**
- Lyme disease, reactive arthritis in, 53**
- Lymecycline, in reactive arthritis, 28-29, 856-857**
 in Reiter's syndrome, 75
- Lymphocytes. See also B lymphocytes; T lymphocytes.**
 in HIV infection. *See Diffuse infiltrative lymphocytosis syndrome.*
 in Sjögren's syndrome, CD4:CD8 ratio in, 540
 histology of, 526
 immunohistologic characterization of, 526
 in salivary glands, 576-579
 in vascular lesions, 612-613
 in vitro studies of, 528-531
 proliferation of, 522
- Lymphocytic alveolitis, in Sjögren's syndrome, 620-621**
- Lymphoma, diffuse infiltrative lymphocytosis syndrome and, 688, 690**
 Sjögren's syndrome and, 512-513, 521-522, 527-528
 in lung, 622-623
 in salivary glands, 576
- Lymphopenia, in SLE, 342-343**
- Lymphoproliferation, in Sjögren's syndrome, 521-522**
- Lysozyme, in tear film, 592-593**
 testing for, 599
- Magnetic resonance imaging, in Sjögren's syndrome, central nervous system, 646-648, 653, 660**
- Major histocompatibility complex. See also Complement system; Human leukocyte antigens.**
 blockade of, in immunotherapy, 920-921
 exogenous peptide binding to, 17-19
 exogenous-endogenous peptide exchange on, 15-16
 genetic organization of, 178-180

- Major histocompatibility complex
 (Continued)
 in diffuse infiltrative lymphocytosis syndrome, 661-662, 693-694
 in rheumatoid arthritis, T-lymphocyte receptor interactions with, 793-808
 in Sjögren's syndrome, 541-542
 central nervous system, 651, 655-656, 660-661
 salivary glands, 578-579
 peptide antigen presentation by, 15
 structure of, 893-894
 Malabsorption, in Sjögren's syndrome, 628
 Male, ankylosing spondylitis in. See *Ankylosing spondylitis, sex hormones in.*
 Markers, disease, genetic factors as, 719-727
 Mas antigens, antibodies to, in polymyositis, 467-468, 475
 Mastitis, in diffuse infiltrative lymphocytosis syndrome, 686
 Membrane attack complex inhibitor, in autoimmune disease, 907
 Membrane cofactor protein, in autoimmune disease, 907
 Methotrexate, in psoriatic arthritis, 251-252
 Mi-2 antigens, antibodies to, in polymyositis, 469, 475
 Mikulicz disease, Sjögren's syndrome and, 508-509
 Mitotic apparatus, autoantibodies to, 562-563
 Mixed connective tissue disease, Ku antigens in, 404
 p70 antibody in, 327
 Mixed lymphocyte culture, in HLA analysis, in rheumatoid arthritis, 763, 765-766
 Modifying factor hypothesis, in ankylosing spondylitis pathogenesis, 97-98
 Molecular mimicry, in ankylosing spondylitis pathogenesis, 98-100, 109-113
 in myositis-specific antibody production, 475-476
 Mononucleosis, infectious, in Sjögren's syndrome pathogenesis, 531-532
 Mouth, Sjögren's syndrome manifestations in. See *Dry mouth; Salivary glands.*
 Multi-modality evoked responses, in Sjögren's syndrome, 649, 653
 Multiple myeloma, anti-Ro antibodies in, 348
 Multiple sclerosis, vs. Sjögren's syndrome, central nervous system, 651-656
 Muscles, involvement of, in ankylosing spondylitis, 167-168, 170
 in HIV infection, 263
 in skin disorders, 215-224
 Myalgia, in Sjögren's syndrome, 707-708
 Myasthenia gravis, immunotherapy in, 917-918
Mycobacterium tuberculosis, in SAPHO syndrome, 239
 Myosin, antibodies to, in polymyositis, 472-473
 Myositis. See *Polymyositis.*
 Naproxen, in juvenile ankylosing spondylitis, 137
 Nasal dryness, in Sjögren's syndrome, 703-704
 Negative selection, of T-lymphocyte populations, rheumatoid arthritis and, 799-800
 Neonatal lupus syndrome, anti-La antibodies in, 360, 363-365
 anti-Ro antibodies in, 347-348, 363-365
 autoantigens in, 552, 558-559
 Neuroimaging, in Sjögren's syndrome, 646-649
 Neutrophils, in vascular lesions, in Sjögren's syndrome, 612-613
 Nonsteroidal anti-inflammatory drugs, gastrointestinal effects of, 25-26
 in juvenile ankylosing spondylitis, 137
 in psoriatic arthritis, 252
 in Sjögren's syndrome, 707-708
 Nuclear autoantigens, 283-310. See also specific antigen.
 antibodies to. See *Antinuclear antibodies.*
 autoimmune epitopes in, 293-294
 in immunoassays, 302-303
 in scleroderma, 484-488
 molecular cloning of, 288-290
 recombinant, as research tools, 291-293
 authentication of, 290-291
 recombinant DNA and, 284-286
 ribonucleoprotein. See *Ribonucleoprotein antigens.*
 RNA recognition of, 291-293
 Nuclear factor IV, structure of, 397
 Nuclear ribonucleoprotein autoantigens, 286-287
 Nucleolar antigens, antibodies to, in scleroderma, 492-494
 Nucleolus organizing region, in scleroderma, 494-495
 Nucleus, antibodies against. See *Antinuclear antibodies.*
 Nystatin, in oral candidiasis, 584-585

- Ocular manifestations, of Sjögren's syndrome. See under *Eye*.
- Ointments, in dry eye, 601-602
- OJ antigens, antibodies to, 464
- Oral contraceptives, ankylosing spondylitis manifestations and, 162
- Oral manifestations, of Sjögren's syndrome. See *Dry mouth*; *Salivary glands*.
- Osteitis, in SAPHO syndrome. See *SAPHO syndrome*.
- Ovine visna maedi virus disease, diffuse infiltrative lymphocytosis syndrome and, 694
- Oxytetracycline, in Reiter's syndrome, 75
- p70 protein, antibodies to, in autoimmune disease, 327
in pathogenesis, 477
species variation in, 399-401
structure of, 394-397
- p80 protein, species variation in, 399-401
structure of, 397
- P proteins, 377-382
antibodies to, clinical associations of, 380-381
epitope recognition by, 379-380
properties of, 381-382
functions of, 379
location on ribosomes, 378-379
molecular weights of, 377-378
- Pancreas, Sjögren's syndrome manifestations in, 629
- Paraneoplastic syndromes, antihistone antibodies in, 424
- Parotid duct, transposition to ocular surface, in dry eye, 605
- p80-coilin, in Sjögren's syndrome, 563-565
- Pediatric patients, spondyloarthropathy in, 7. See also *Ankylosing spondylitis, juvenile*.
- Penicillamine, in psoriatic arthritis, 252
- Penicillin, in Reiter's syndrome, 87
- Peptides, antigens of, presented by HLA-B27, 848-850
binding of, by HLA antigens, in rheumatoid arthritis, 732-733
in Ro antigens, 339-340
in spondyloarthropathy. See *Arthritogenic peptide model*.
mapping of, in autoantigen authentication, 292
- Peptidoglycans, antibodies to, in spondyloarthropathies, 857
- Periodontal disease, in Sjögren's syndrome, 702
- Phenylbutazone, in polyarthralgia, 209
- Physiotherapy, in juvenile ankylosing spondylitis, 137
- Picornaviruses, in myositis-specific antibody production, 475-476
- Pilocarpine, in Sjögren's syndrome, 585-586
dry eye, 605
dry mouth, 703
- PL-7 antigens, antibodies to, diagnostic use of, 473
epitopes of, 466
- PL-12 antigens, antibodies to, 459, 463
epitopes of, 466
- Plasmapheresis, in Sjögren's syndrome, 666
- Pleocytosis, in Sjögren's syndrome, 649
- PM-Scl antigens, antibodies to, in polymyositis, 469-470, 475, 477
in scleroderma, 493-494
- Pneumonia, in Sjögren's syndrome, 619
- Pneumonitis, interstitial, in Sjögren's syndrome, 621-622
- Po idiotype, of immunoglobulin M, 814-815
- Polyarthralgia, 203-213
clinical signs of, 204-205
criteria for, 203-204
familial occurrence of, 207-208
laboratory findings in, 204, 207
pathology of, 207
prognosis for, 209
radiologic findings in, 204
symptoms of, 204
treatment of, 209
- Polymyositis, antibodies in, 455-482
diagnostic use of, 473-474
in pathogenesis, 476-477
myositis-specific, 473-477
nonspecific, 471-473
production of, mechanisms of, 474-476
to aminoacyl-tRNA synthetases, 455-466
to cytoplasmic antigens, 466-468
to nuclear antigens, 468-471
overlap with scleroderma, antiribonucleoprotein antibodies in, 328
Ku antigens in, 393, 403-404
- Polypeptides, in ribonucleoproteins, 312, 314-317
- Population genetics, of HLA-B27, 842-843
of rheumatoid arthritis, 741-759, 767-769
HLA genotyping and, 785-792
of spondyloarthropathy, 837-838
- Positive selection, of T-lymphocyte populations, rheumatoid arthritis and, 737, 799-800
- p70/p80 antigen. See *Ku antigens*.

- Precipitin, lupus. See *Sm antigens*, in *SLE*, antibodies to.
- Prednisone, in diffuse infiltrative lymphocytosis syndrome, 689
- Pregnancy, ankylosing spondylitis in, 161
- Procainamide-induced lupus, antihistone antibodies in, 422, 430-431
- Procollagen, type VII, antibodies to, in *SLE*, 880-881
- Propionibacterium acnes*, in *SAPHO* syndrome, 237, 239-240
- Proteasomes, relationship to HLA genes, 850
- PSE1 transcription factor, structure of, 398
- Pseudolymphoma, Sjögren's syndrome and, 512-513, 521-522
- pulmonary, 622-623
- Psoriasis, genetic factors in, 839
- Psoriatic arthritis, 247-256
- clinical features of, 248
- environmental factors in, 250-251
- genetic factors in, 248-249, 839
- immunologic mechanisms in, 249-250
- in HIV infection, 261-262, 855
- pathogenesis of, 248-251
- prevalence of, 248
- trauma in, 251
- treatment of, 251-253
- Psychosis, lupus, anti-P antibodies in, 379-381
- Pulmonary disease, in juvenile ankylosing spondylitis, 132
- Punctal occlusion, in dry eye, 602-604, 701
- Purpura, in Sjögren's syndrome, 610-611
- Pustulosis, in *SAPHO* syndrome. See *SAPHO syndrome*.
- PUVA therapy, in psoriatic arthritis, 251
- Radioimmunoassay, for antihistone antibodies, 417-418
- Radioimmunoprecipitation assay, for antiribonucleoprotein antibodies, 323
- Raynaud's disease, anticentromeric antibodies in, 486-487
- antitopoisomerase I antibodies in, 490
- in antisynthetase syndrome, 461-462
- Raynaud's phenomenon, in Sjögren's syndrome, 610
- Reactive arthritis. See also *Reiter's syndrome*.
- antibiotic therapy in, 856-857
- bacterial antigens in, 37-48, 49-66
- antigen presenting cell in, 57
- HLA-B27 and, 59-60
- identification in joint, 50-51
- immune response in, 51-59
- immune system in, 39-40
- lipopolysaccharide role in, 37-38, 43-44
- microbe-host interaction in, 38
- microorganism types, 37-38, 40-43
- superantigens, 58
- T cell role in, 55-57
- transportation to joints, 43
- epidemiology of, 839-840
- gastrointestinal system and, 23-24, 27-28
- genetic factors in, 839-840
- immune complexes in, 855-856
- in ankylosing spondylitis pathogenesis, 27-28
- in HIV infection, 260-261
- treatment of, 28-30
- Reiter's syndrome, bacterial antigen persistence in, 856
- chlamydial infections and, 67-79
- cellular injury mechanisms, 72-75
- latent, 73-75
- microorganism presence in synovium, 69-72
- pathogenesis of, 68-69
- treatment of, 75
- epidemiology of, 839-840
- HIV infection and, 267-276
- genetic factors in, 839-840
- in HIV infection, 260-261, 267-276
- postvenereal, 81-93
- epidemiology of, 81-85
- family studies in, 89-90
- treatment of, 85-90
- Remitting seronegative symmetrical synovitis with pitting edema, vs. late-onset spondyloarthritis, 193, 195
- Respiratory infections, in Sjögren's syndrome, 619
- Retinoids, in psoriatic arthritis, 251-252
- in *SAPHO* syndrome, 240
- Retroviruses, in Sjögren's syndrome pathogenesis, 532
- Rhabdoviruses, anti-Ro antibodies and, 353
- Rheumatoid arthritis, antcentromeric antibodies in, 486-487
- antihistone antibodies in, 423
- clinical manifestations of, HLA genotyping and, 787-790
- complement receptor 2 deficiency in, 905-906
- environmental factors in, 731, 761-762, 795
- genetic factors in, 729-740. See also *Rheumatoid arthritis, population genetics of; Shared epitope hypothesis*.
- environmental factors and, 731, 795
- HLA genotyping and, 785-792
- immunoglobulin V genes in, 809-836
- immunologic factors and, 731-738

- limitations of, 729-730
 population associations in. See subhead: *population genetics of*.
 T-cell receptors in, 785-792
- HLA genotyping in, 785-792
 juvenile. See *Juvenile rheumatoid arthritis*.
 molecular genetics of, 762-777
 negative allele associations in, 752-753
 partial penetrance in, 762
 pathogenesis of, 729-740. See also subhead: *genetic factors in*.
 environmental factors in, 731, 795
 immunologic factors in, 731-738
 population associations and, 741-759
 synovitis, 738
 T-lymphocyte receptor-HLA interaction in, 793-808
- population genetics of, 741-759, 767-769
 amino acid-DNA sequencing studies in, 745-746
 class II epitopes in, 745
 HLA genotyping and, 785-792
 HLA-DP associations in, 753
 HLA-DQ associations in, 753
 HLA-DR4 heterogeneity and, 741-743
 in specific countries, 743-745, 748-749
 negative allele associations in, 752-753
 shared epitopes in, 746-752
 predictive risk ratios for, 790-791
 severity of, shared epitopes and, 750-752
- shared epitope hypothesis in. See under *Shared epitope hypothesis*.
 susceptibility to. See also subhead: *genetic factors in*.
 HLA genotyping in, 785-792
 immunoglobulin V gene polymorphisms in, 826-828
 synovitis in, pathogenesis of, 738
 T-lymphocyte receptor-HLA interaction in, 793-808
- collagen-induced arthritis disease model and, 801-802
 general model for, 795-798
 HLA polymorphism in, 798-799
 thymic selection and, 799-802
 T-lymphocyte repertoire and, 802-804
- Rheumatoid factors, cross reactivity with antihistone antibodies, 427
 immunoglobulin paraproteins as, 812-818
 in diffuse infiltrative lymphocytosis syndrome, 687
 in normal individuals, immunoglobulin V gene use in, 818-819
 in rheumatoid arthritis, 732
 disease severity and, 751
- immunoglobulin V gene use in, 819, 822-828
 in Sjögren's syndrome, 522-523, 650
- Ribonucleoprotein antigens, 286-287. See also specific antigen, e.g., *SS-B/La antigen*; *Sm antigens*.
 antibodies to, in SLE, 311-335
 characterization of, 312-314
 clinical association of, 325-328
 detection of, 319-325
 function of, 312-314
 genesis of responses in, 328-329
 intracellular assembly of, 318-319
 structure of, 314-317
 polypeptides in, 312, 314-317
 protein components of, 314-317
 uridine-rich small nuclear. See *U snRNP antigens*.
- Ribosomes, antibodies to. See *Antiribosomal antibodies*.
- Ribs, SAPHO syndrome effects on, 227, 229-230
- RNA, in ribonucleoproteins. See *Ribonucleoprotein antigens*.
 nuclear, 286-287
 nuclear autoantigen interactions with, 293-294
 types of, 286-287
- RNA polymerase I, antibodies to, in scleroderma, 492-493
- 7-2 RNA protein particle, in scleroderma, 494
- Ro antigen. See *SS-A/Ro antigen*.
- Rose Bengal dye, in tear flow assessment, 597
- 28S rRNA, antibodies to, 382-384
- S10 subunit protein, antibodies to, 384
- Sacroiliitis, in juvenile ankylosing spondylitis, 129
 in skin disorders, 217-218
 in undifferentiated spondyloarthropathy, diagnosis and, 193-196
 epidemiology of, 189-193
 prognosis for, 196-198
- SAPHO syndrome effects on, 233
- Salazopyrin, in polyarthralgia, 209
- Saliva, flow of, factors affecting, 580-581
 in Sjögren's syndrome, 519-521, 582-583, 585-586
 in Sjögren's syndrome, 519-521
 assessment of flow, 582-583
 characteristics of, 572, 574
 chemical composition of, 583
 stimulation of flow, 585-586
 substitutes for, 586

- Salivary glands, diffuse infiltrative lymphocytosis manifestations in, 685, 687-688, 693
- enlargement of, differential diagnosis of, 581
- in diffuse infiltrative lymphocytosis syndrome, 685
- in Sjögren's syndrome, 573-574
- Sjögren's syndrome manifestations in, 571-589, 624-625
- autoantibodies against, 522
- biopsy of, 582
- clinical features of, 572-576
- diagnosis of, 582-583
- differential diagnosis of, 580-581
- enlargement of, 573-574
- histology of, 525-526
- immunopathology of, 576-580
- management of, 583-586
- pathogenesis of, 519-521, 532-533
- pathology of, 576-580
- scintigraphy of, 583
- Salmonella* infections, in spondyloarthropathies, 851, 857
- reactive arthritis in, 23-24, 37-39, 41-44
- Sandwich solid-phase assay, for anti-Ro antibodies, 340
- SAPHO syndrome, **225-246**
- alternate names for, 226
- clinical description of, bone involvement, 227-234
- joint involvement, 227, 229
- skin involvement, 235-236
- course of, 237
- diagnosis of, 238-239
- epidemiology of, 226
- laboratory findings in, 237-238
- nosology of, 239
- pathophysiology of, 239-240
- treatment of, 240
- Scalp, dissecting cellulitis of, musculoskeletal features of, **215-224**
- in follicular occlusion triad, 216-217
- laboratory evaluation of, 218-219
- treatment of, 219
- Schirmer test, in dry eye, 598-599, 675-677
- Scintigraphy, of salivary glands, 583
- Scl-70. See *Topoisomerase I*.
- Scleroderma, antibodies in, **483-498**
- rare, 494-495
- to 7-2 RNA protein particle, 494
- to centromere, 484-488
- to fibrillarin, 493
- to nuclear antigens, 484-492
- to nucleolar antigens, 492-494
- to nucleolus organizing region, 494-495
- to RNA polymerase I, 492-493
- to topoisomerase I, 488-492
- Scleroderma-polymyositis overlap syndrome, antiribonucleoprotein antibodies in, 328
- Ku antigens in, 393, 403-404
- PM-Scl antigen in, 469-470
- SEA (seronegative enthesopathy and arthropathy) syndrome, 133
- Self-tolerance, failure of, in Sjögren's syndrome, 522-523, 525
- Septic arthritis, in HIV infection, 263
- Seronegative enthesopathy and arthropathy syndrome, 133
- Sex hormones, in ankylosing spondylitis. See under *Ankylosing spondylitis*.
- Shared epitope hypothesis, in rheumatoid arthritis, 732-738, **761-783**
- family studies in, 761-762
- HLA genotyping and, **785-792**
- homozygosity in, 776-777
- human specificity in, 737-738
- mapping susceptibility location in, 768-774
- molecular genetics background and, 762-777
- population associations in, 746-752
- relationship to formal genetics, 777-780
- T lymphocyte tolerance in, 734-736
- testing of, 774-776
- twin studies in, 761-762
- Shigella* infections, in spondyloarthropathies, 851, 853
- reactive arthritis in, 23, 37-39, 43
- Sialochemistry, in Sjögren's syndrome, 583
- Sialogogues, in Sjögren's syndrome, 585
- Sialography, in Sjögren's syndrome, 583
- Sialometry, in Sjögren's syndrome, 582-583
- Sicca symptoms. See also entries starting with *Dry*.
- in HIV infection. See *Diffuse infiltrative lymphocytosis syndrome*.
- Signal recognition particle (SRP) antigens, antibodies to, in polymyositis, 467, 475, 477
- SjD antigen. See *SS-B/La antigen*.
- Sjögren's syndrome, anticomeric antibodies in, 486
- anti-La antibodies in, 359-363, 367-369
- anti-Ro antibodies in, 338-339, 341-342, 359-360, 362-364
- autoantibodies in. See under *Autoantibodies*.
- central nervous system, 665-666
- "autoimmune trait" in, 548
- celiac disease with, 628
- central nervous system manifestations of, 614, **637-671**

- clinical manifestations of, 643
 central nervous system, 644-645
 ocular, 594-598
 salivary glands, 572-576
 spectrum of, 507-515
 vascular lesions, 610-612
- Crohn's disease with, 628
- cutaneous manifestations of, 609-616
- diagnosis of, 643-644
 central nervous system, 647-651
 ocular, 598-600, 675-677
- epidemiology of, 518-519
- esophageal manifestations of, 625-627
- estrogen therapy in, 705
- gastrointestinal manifestations of, 623-635
- genetic factors in, 523-525, 539-550
 central nervous system, 651
- histologic features of, pathogenesis of, 525-526
- historical overview of, 507-515
- HIV infection and. See *Diffuse infiltrative lymphocytosis syndrome*.
- immune tolerance in, 523, 525
- immunogenetics of, 539-550
 central nervous system, 651
- immunoglobulin DNA rearrangement in, 526-528
- immunopathogenesis of, central nervous system, 662-664
- in HIV infection, 342
- liver manifestations of, 629-630
- lymphocyte function in. See under *Lymphocytes*.
- lymphocytic infiltration in, of lung, 619-623
- lymphoma development in. See under *Lymphoma*.
- lymphoproliferative features of, 521-522
- ocular manifestations of. See under *Eye*.
- oral features of. See *Dry mouth*; *Salivary glands*.
- pancreatic manifestations of, 629
- pathogenesis of, 517-538
 autoantibodies, 522-523, 525
 central nervous system, 665-666
 genetic factors in, 523-525, 539-550
 histologic features, 525-526
 immune tolerance, 523, 525
 immunoglobulin DNA rearrangement, 526-528
 lymphocyte function, 528-531
 lymphoproliferative features, 521-522
 model of, 532-534
 ocular features, 519-521
 oral features, 519-521
 viral cofactors, 531-532, 579-580
- primary, 510
- pulmonary manifestations of, 617-623
- salivary gland manifestations of. See under *Salivary glands*.
- secondary, 510-511
- small intestinal manifestations of, 628
- tracheobronchial desiccation in, 618-619
- treatment of, 673-682, 699-709
 arthralgia, 707-708
 central nervous system, 666-668
 depression, 707
 dry eye, 601-606, 677-679, 700-702
 dry mouth, 583-586, 702-703
 dry nose, 703-704
 dry skin, 704
 fatigue, 706-707
 herbal medicines in, 679-682
 in Japan, 673-682
 medication side effects in, 708-709
 myalgia, 707-708
 vaginal dryness, 704-706
 vascular disease and, 664-665
 vascular lesions in, 610-614
 viral cofactors in, 531-532
 vs. Alzheimer's disease, 646
 vs. diffuse infiltrative lymphocytosis syndrome, 684
 vs. multiple sclerosis, 651-656
 vs. systemic lupus erythematosus, 656-661
- Waldenström's hypergammaglobulinemia with, 611
- Sjögren's syndrome-lupus overlap disease, 615
 anti-Ro antibodies in, 346-347
 SjT antigen. See *SS-A/Ro antigen*.
- Skin disorders, in SAPHO syndrome. See *SAPHO syndrome*.
- in Sjögren's syndrome, 609-616
 lupus erythematosus overlap, 615
 vascular lesions, 610-614
 xerosis, 609-610, 704
- in spondyloarthropathy, 215-224
- SLE. See *Systemic lupus erythematosus*.
- Sm antigens, authentication of, 292
 in SLE, antibodies to, 879
 clinical association of, 325-326
 detection of, 319-325
 discovery of, 311
 genesis of responses in, 328-329
 characterization of, 313-314
 function of, 313-314
 intracellular assembly of, 318-319
 structure of, 312, 314-317
 protein components of, 314-317
- Small intestine, Sjögren's syndrome manifestations in, 628
- Specificity, of human leukocyte antigens, 763
- Spine, juvenile ankylosing spondylitis effects on, 129

Spine (*Continued*)

SAPHO syndrome effects on, 227, 229-230, 233

Spondyloarthropathy. *See also Ankylosing spondylitis; Reactive arthritis; Reiter's syndrome; Psoriatic arthritis.*

animal models for, 851

classification of, 6-7

clinical aspects of, HIV infection and, 260-263

enthesopathy in. *See Enthesopathy.*

epidemiology of, 1-2, 839-840

HIV infection and, 258-259

follicular occlusion triad in, 216-217

gastrointestinal system and, 23-35. *See also Bacterial antigens.*

genetic factors in, 837-864

bacterial antigen persistence and, 855-858

bacterial triggers and, 851-855

epidemiology of, 839-840

etiology of, 840-842

HLA-B27, gene organization of, 843-847

peptide antigens presented by, 848-850

structure of, 843-847

subtypes of, 842-843

transgenic rat model for, 851

population associations in, 837-838

proteasome genes, 850

transporter genes, 850

HIV infection and, 257-266, 855

HLA-B27 and, 1-6, 11-21

arthritogenic peptide model and, 11-21

ileal bypass arthritis, 24

in acne, 215-224

in children, 7

in hidradenitis suppurativa, 215-224

in non-Caucasian populations, 4-6

in scalp dissecting cellulitis, 215-224

inflammatory bowel disease arthritis, 24

laboratory findings in, HIV infection and, 263

nonsteroidal anti-inflammatory drugs in, gastrointestinal inflammation and, 25-26

overview of, 1-10

pathogenesis of, 11-21

gastrointestinal system and, 27-28

polyenthesitis in, 203-213

SAPHO syndrome, 225-246

skin disorders in, 215-224

treatment of, gastrointestinal inflammation and, 28-30

undifferentiated, 187-202

clinical features of, 191-193

definition of, 188

diagnosis of, 193-194

differential diagnosis of, 194-196

epidemiology of, 189-193

familial factors in, 190-191

HIV infection and, 262-263

prognosis for, 196-198

terminology of, 188-189

treatment of, 198

uveitis in, 143-151

characterization of, 144

differential diagnosis of, 147

etiology of, 148

HLA-B27 and, 145-147

treatment of, 148-149

SRP antigens, antibodies to, in

polymyositis, 467, 475, 477

SS-A/Ro antigen, 337-358

antibodies to, detection of, 338-340

HLAs and, 343-346

in clinical specimens, 341

in lupus with complement deficiencies, 347

in multiple myeloma, 348

in neonatal lupus syndrome, 347-348, 363-365

in rheumatoid conditions, 348-349

in Sjögren's syndrome, 341-342, 359-360, 362-364

in Sjögren's syndrome-lupus overlap disease, 346-347

in SLE, 342-346, 359-363

in subacute cutaneous lupus erythematosus, 347

origins of, 349-354

detection of, 338-340

in diffuse infiltrative lymphocytosis syndrome, 687

in Sjögren's syndrome, 552-559

antibodies to, 522, 540, 545-547

calreticulin and, 556-557

central nervous system, 650-651, 655, 660, 663-666

expression of, 557-559

molecular cloning of, 553-556

in SLE, 873-874, 876-877

La antigen associations of, 359-361, 365

purified, preparation of, 340

recombinant, 340

RNA recognition of, 291

types of, 340

SS-B/La antigen, antibodies to, 359-376

clinical correlations of, 362-365

historical perspectives of, 359-361

HLA associations of, 361-362

immunochemical properties of, 367-368

in neonatal lupus syndrome, 360, 363-365

in Sjögren's syndrome, 359-363, 367-369

in SLE, 360-363, 367-371

- production of, animal models of, 370-371
 - serologic correlations of, 362-365
 - specificity of, 368-369
- cloning of, 288
 - authentication of, 290
- epitopes within, 294-295
- in Sjögren's syndrome, 559-562
 - antibodies to, 540, 545-547
 - autoepitope of, 561-562
 - expression of, 560-561
 - function of, 561
 - molecular cloning of, 560
- in SLE, 360-363, 367-371, 873-874, 876-877
 - RNA recognition of, 291
 - Ro antigen associations of, 359-361, 365
 - structure of, 365-367
- SS-DNA antigen, in Sjögren's syndrome, antibodies to, 540
- Stomach, Sjögren's syndrome
 - manifestations in, 627
- Subacute cutaneous lupus erythematosus, autoantigens in, 552, 558-559
- Sulfasalazine, in ankylosing spondylitis, 29-30
 - in HIV-related spondyloarthropathy, 264
 - in juvenile ankylosing spondylitis, 137
 - in psoriatic arthritis, 252
 - in SAPHO syndrome, 240
 - in undifferentiated spondyloarthropathy, 198
- Superantigens, in reactive arthritis, 58
 - in rheumatoid arthritis, 796-797
- Surgery, in psoriatic arthritis, 253
- Sweet's syndrome, in Sjögren's syndrome, 611
- Synovitis, in rheumatoid arthritis, pathogenesis of, 738
 - in SAPHO syndrome. See *SAPHO syndrome*.
- Systemic lupus erythematosus, angioedema in, 907
 - anticentromeric antibodies in, 486
 - anti-DNA antibodies in, animal models for, 441-442
 - clinical expression of, 438-440
 - idiotype interactions and, 448-450
 - immunopathology of, 440-441
 - molecular analysis of, 445-448
 - production of, mechanisms of, 443-445
 - antihistone antibodies in, 419-421
 - animal models of, 424-426
 - diagnostic value of, 430-431
 - in drug-induced lupus, 430-431
 - production mechanism of, 427-430
 - anti-La antibodies in, 360-363, 367-371
 - antiphospholipid antibodies in, 878
- antiribonucleoprotein antibodies in, 311-335
 - characterization of, 312-314
 - clinical association of, 325-328
 - detection of, 319-325
 - function of, 312-314
 - genesis of responses in, 328-329
 - intracellular assembly of, 318-319
 - structure of, 314-317
- antiribosomal antibodies in, 377-390
 - animal models of, 384-385
 - P protein, 377-382
 - 28S rRNA, 382-383
 - subunit protein 510, 384
- anti-Ro antibodies in, 339, 342-346, 359-363
 - complement gene defects in, 866-871
 - C1q deficiency, 867-868
 - C1r deficiency, 868
 - C1s deficiency, 868
 - C2 deficiency, 870-871
 - C4 deficiency, 868-870, 896-898
 - complement receptor abnormalities in, 900-905
 - complement receptor autoantibodies in, 903-904
 - genetic factors in, 865-892
 - complement gene defects, 866-871
 - immunoglobulin genes, 882-883
 - major histocompatibility complex antigens, 871-882
 - T-cell receptor genes, 882
 - tumor necrosis factor genes, 883
 - glomerulonephritis in, anti-DNA antibodies in, 440-441
 - antihistone antibodies in, 432
 - HLA associations with, 871-882
 - Ku antigens in, 391-414
 - antibodies to, 403-410
 - autoimmune mechanisms in, 409-410
 - in animal models, 406-408
 - specificities of, 404, 406-408
 - function of, 402-403
 - interaction with DNA, 401-402
 - structure of, 393-401
 - overlap with Sjögren's syndrome, 346-347, 615
 - SS-A/Ro antigen in, 873-874, 876-877
 - SS-B/La antigen in, 873-874, 876-877
 - tumor necrosis factor polymorphism in, 181-182
 - vs. Sjögren's syndrome, central nervous system, 656-661
- Systemic sclerosis. See *Scleroderma*.
- T lymphocyte(s), cytotoxic, in spondyloarthropathies, 841-842

- T lymphocyte(s) (*Continued*)
 human repertoire of, 802-804
 in antihistone antibody production, 428
 in psoriatic arthritis, 249-250
 in reactive arthritis, 55-57
 in rheumatoid arthritis, 778-779
 interaction with HLA antigens, 732-733, 793-808
 tolerance to shared epitopes, 734-736
 in ribonucleoprotein response, 328-329
 in SLE, 344-345
 monoclonal antibodies against, immunotherapy with, 919-920
- T-lymphocyte receptors, antigens of, antibodies to, in Sjögren's syndrome, 541
- Tar formulations, in psoriatic arthritis, 251
- Tarsorrhaphy, in dry eye, 605
- Tears, artificial, 596, 601-602, 679, 700-701
 conservation of, in dry eye, 602-604
 evaporation of, measurement of, 677
 flow of, deficient. *See Dry eye.*
 in Sjögren's syndrome, 519-521
 normal, 591-594
- Testosterone, ankylosing spondylitis manifestations and, 162-165
- Tetracyclines, in Reiter's syndrome, 75, 87-88
- Th antigens (7-2 RNA protein particle), antibodies to, in scleroderma, 494
- Thoracic outlet syndrome, in SAPHO syndrome, 236
- Threonyl-tRNA synthetase, antibodies to (anti-PL-7), 473
- Thymic selection, of T-lymphocyte populations, rheumatoid arthritis and, 799-802
- Tietze's syndrome, SAPHO syndrome and, 236, 547-548
 genes of, in SLE, 882
 immunotherapy based on, 921-923
 in rheumatoid arthritis, HLAs and, 772-774, 793-808
- Tolmetin, in juvenile ankylosing spondylitis, 137
- Tongue, Sjögren's syndrome manifestations in, 572, 702-703
- Topoisomerase I, antibodies to, anticentromeric antibodies and, 491-492
 association with cancer, 490
 detection of, 489
 HLA associations of, 490
 idiotypes of, 490-491
 in scleroderma, 489-492
 epitopes of, 490-491
 structure of, 488-489
- Tracheobronchial desiccation, in Sjögren's syndrome, 618-619
- Translation-related antigens, antibodies to, in polymyositis, 468
- Transporter genes, relationship to HLA genes, 850
- Trauma, in psoriatic arthritis pathogenesis, 251
- TREX transcription factor, structure of, 398
- Trimethoprim-sulfamethoxazole, in HIV-related spondyloarthropathy, 264
- Tumor necrosis factor, deficiency of, in SLE, 883
 polymorphism of, ankylosing spondylitis and, 177-186
 cytokine production and, 181
 genetic aspects of, 178-181
 restriction fragment length polymorphism analysis in, 180, 183
- U snRNP (uridine-rich small nuclear ribonucleoprotein) antigens, antibodies to, clinical association of, 326-328
 detection of, 319-321
 genesis of response in, 328-329
 in polymyositis, 472
 in SLE, 879-880
 characterization of, 312-314
 structure of, 312
- Ulcerative colitis, genetic factors in, 839
- Undifferentiated spondyloarthropathy. *See under Spondyloarthropathy.*
- Urethritis, reactive arthritis in. *See also Reiter's syndrome.*
 immune response in, 52-53
- Urticaria, in Sjögren's syndrome, 610-612
- Uveitis, in juvenile ankylosing spondylitis, 131-132
 in spondyloarthropathy, 143-151, 857-858
 characterization of, 144
 differential diagnosis of, 147
 etiology of, 148
 HLA-B27 and, 145-147
 treatment of, 148-149
- Vaginal dryness, in Sjögren's syndrome, 704-706
- Vascular lesions, in HIV infection, 263
 in Sjögren's syndrome, central nervous system, 662-665
 cutaneous, 610-614
 clinical manifestations of, 610-612
 pathology of, 612-613
 serology of, 613
 significance of, 614

- Vesicular stomatitis virus, anti-Ku antibodies and, 409
 anti-Ro antibodies and, 350, 352-353
 Viral infections. See also *Human immunodeficiency virus infection*.
 in myositis-specific antibody production, 475-476
 juvenile ankylosing spondylitis and, 126
 Viruses, in Sjögren's syndrome
 pathogenesis, 531-532, 579-580
 Visna maedi virus disease, ovine, diffuse infiltrative lymphocytosis syndrome and, 694
 Vitamin A, in dry eye, 605
 in tear film, 594
 Vitamin D, in psoriatic arthritis, 252
- Wa idotype, of immunoglobulin M, 812-814
 Waldenström's hypergammaglobulinemia, Sjögren's syndrome with, 611
- Xerosis, in Sjögren's syndrome, 609-610, 704
 Xerostomia. See *Dry mouth*.
 Xerotrachea, in Sjögren's syndrome, 618-619
- Yersinia infections, in spondyloarthropathies, 851, 855-857
 reactive arthritis from, 23-24, 37-44, 51-52
- Zidovudine, in diffuse infiltrative lymphocytosis syndrome, 688-689
 in HIV-related spondyloarthropathy, 264
 myopathy from, 263